纳米医学
前药
材料科学
免疫疗法
癌症免疫疗法
癌症研究
癌症治疗
癌症
纳米技术
药理学
纳米颗粒
医学
内科学
作者
Bin Wang,Jingyu Zhou,Ruitong Li,Dongsheng Tang,Yunfeng Lu,Chun Xu,Haihua Xiao
标识
DOI:10.1002/adma.202311640
摘要
Abstract Recent years have witnessed substantial progress in cancer immunotherapy, specifically T cell‐based therapies. However, the application of T cell therapies has been primarily limited to hematologic malignancies, with limited success in the treatment of solid tumors. The main challenge in treating solid tumor is immune escape, which is characterized by reduced antigenicity, diminished immunogenicity, and the development of suppressive tumor immune microenvironments. To address these obstacles and restore T cell‐mediated anti‐tumor responses, we have developed a novel nanoparticle formulation known as PRA@Oxa‐c16. This innovative approach combines retinoic acid and Pt(IV) to specifically target and overcome immune escape. Notably, the therapeutic efficacy of PRA@Oxa‐c16 primarily relies on its ability to induce anti‐tumor T cell responses, in contrast to the cytotoxicity associated with conventional chemotherapeutic agents. When combined with an immune checkpoint blockade, anti‐programmed death‐ligand 1 antibody, PRA@Oxa‐c16 effectively eliminates solid tumors and induces immune memory responses, which prevent tumor metastasis and recurrence. This promising approach holds great potential for enhancing the treatment of solid tumors with T cell‐based immunotherapy. This article is protected by copyright. All rights reserved
科研通智能强力驱动
Strongly Powered by AbleSci AI